Please login to the form below

Not currently logged in
Email:
Password:

Repligen

This page shows the latest Repligen news and features for those working in and with pharma, biotech and healthcare.

Biogen buys into Ionis' nusinersen after positive phase III trial

Biogen buys into Ionis' nusinersen after positive phase III trial

Other companies working on therapies for SMA includeand Pfizer/Repligen.

Latest news

  • Pfizer acquires spinal muscular atrophy research programme Pfizer acquires spinal muscular atrophy research programme

    Gains rights to drug candidate RG3039 in deal with Repligen that could be worth up to $70m. ... $5m. The main candidate involved in the programme is RG3039, which will undergo phase I trials carried out by Repligen in the first quarter of 2013.

  • Oncology bias in pharma deals

    112. Syntaxin/Ipsen. Research and development collaboration. Botulinum toxins. 99. Novozymes Biopharma Sweden/Repligen Corp.

  • Repligen bipolar drug fails in study

    An oral form of uridine being developed by Repligen as a potential treatment for bipolar depression failed to show efficacy in a late-stage clinical trial. ... However, Repligen noted that a preliminary analysis indicates that in the 50 patients in the

  • State of mind

    RG 2417. Repligen. Bipolar disorder. Anticonvulsants. Anticonvulsants, such as lamotrigine and valproic acid, have been found useful as mood stabilisers, preventing the extremes of mania and depression in patients with bipolar ... RG 2417 (Repligen) is a

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Pharma deals during January 2013 Pharma deals during January 2013

    Repligen announced the signature of an exclusive worldwide licensing agreement with Pfizer to advance Repligen's spinal muscular atrophy (SMA) programme. ... Repligen will receive up to $70m from Pfizer with an upfront payment of $5m and future

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...

Infographics